AbbVie (ABBV) Long-Term Investments (2012 - 2026)

AbbVie (ABBV) has reported Long-Term Investments for 15 consecutive years, with $268.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments fell 6.62% year-over-year to $268.0 million; the TTM figure through Mar 2026 stood at $268.0 million (down 6.62% YoY), while the FY2025 annual figure was $268.0 million, down 3.94% from the prior year.
• Long-Term Investments steadied at $268.0 million in Q1 2026 per ABBV's latest filing, from $268.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $310.0 million in Q2 2025 and bottomed at $235.0 million in Q3 2022.
• Historically, Long-Term Investments has averaged $273.6 million across 5 years, with a median of $272.0 million in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Investments retreated 14.75% — and 2023, when it grew 26.14%.
• AbbVie's Long-Term Investments stood at $241.0 million in 2022, then grew by 26.14% to $304.0 million in 2023, then slipped by 8.22% to $279.0 million in 2024, then declined by 3.94% to $268.0 million in 2025, then changed by 0.0% to $268.0 million in 2026.
• Business Quant data shows ABBV's Long-Term Investments at $268.0 million in Q1 2026, $268.0 million in Q4 2025, and $291.0 million in Q3 2025.